AlphaYou
Overview
Smart money at a glance
Filings to Oct 13, 2026Net buying: insiders sold $0 and bought $67K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$67K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 13- Open
- $1.10
- 52-wk high
- $6.12
- High
- $1.11
- 52-wk low
- $0.96
- Low
- $1.05
- Prev close
- $1.12
- Mkt cap
- $10.2M
- Volume
- 39.7K
- Beta
- 0.76
- P/S
- 0.8x
- P/B
- 3.3x
- Profit margin
- -59.7%
- Op margin
- -122.9%
- ROE
- -124.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about NMTC filings
Are insiders buying or selling Neuroone Medical Technologies Corp (NMTC) stock?
Net buying: insiders sold $0 and bought $67K of NMTC stock on the open market in the 90 days to Oct 13, 2026, according to SEC Form 4 filings. The largest was Wambeke, David J. (Chief Business Officer), who bought $67K. The latest filing was on Sep 8, 2026.
Which members of Congress have traded NMTC recently?
None. No member of Congress disclosed a NMTC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this NMTC smart-money data?
This summary uses filings available on Oct 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
4 funds hold a position and insiders are trading both ways.
What insiders are doing
Buys (1)
- WD
Wambeke David J.
$67K
bought
Sells (1)
- CM
Christianson Mark
$32K
sold
How top traders are positioned
No tracked top-trader positions in NMTC right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 8.4% below what analysts expected.
Last report
May 12, 2026
Period ending
Mar 31, 2026
Earnings per share
-$0.23 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Mar 31, 2026 | May 12, 2026 | -$0.25 / -$0.23Alpha Vantage | -8.43% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 17, 2026 | -$0.18 / -$0.24Alpha Vantage | +25.00% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Dec 17, 2025 | -$0.03 / -$0.06Alpha Vantage | +$0.03 beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 14, 2025 | -$0.18 / -$0.30Alpha Vantage | +40.00% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 13, 2025 | -$0.42 / -$0.54Alpha Vantage | +22.22% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 12, 2025 | $0.36 / -$0.60Alpha Vantage | +$0.96 beat | Unavailable | Unavailable |
| Sep 30, 2024 | Dec 17, 2024 | -$0.11 / -$0.09Alpha Vantage | -$0.02 miss | Unavailable | Unavailable |
| Jun 30, 2024 | Aug 14, 2024 | -$0.10 / -$0.09Alpha Vantage | -$0.01 miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
What the street expects next
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -59.7%
- Market cap
- $10M
Valuation
- P/S0.82
- P/B3.25
Quality
- Operating margin-122.9%
- ROE-124.7%
- ROA-58.1%
Growth
- Beta0.76
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace